Nobiletin, a citrus-peel compound sold as a dietary supplement for the body's daily clock, metabolism, and brain health, shows striking animal results. Human evidence is thin: small trials of mixed citrus products suggest modest memory gains and less night-time urination. Trials link no consistent side effects, but laboratory data point to possible effects on blood clotting and on how the liver clears common medicines. Overall, low-risk but largely unproven. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Fasting glucose | 75–90 mg/dL | Glycemic response |
| HbA1c | 4.8–5.3% | 3-month glycemic trend |
| Fasting insulin | 2–6 µIU/mL | Insulin sensitivity |
| LDL-C | Below 100 mg/dL | Lipid response (conflicting evidence) |
| Triglycerides | Below 100 mg/dL | Metabolic response |
| ALT and AST | Below 25 U/L each | Liver safety |
| Creatinine and eGFR | eGFR above 90 mL/min/1.73 m² | Kidney function baseline |
| Platelet count | 150,000–400,000/µL | Bleeding risk baseline |
| INR (warfarin users only) | Individual target set by prescriber, usually 2.0–3.0 | Detect interaction |
| Levels of CYP-dependent drugs (tacrolimus, cyclosporine, theophylline) | Prescriber's therapeutic range | Detect interaction |
Cadence: Baseline before starting; INR or drug levels at 1–2 weeks after starting when interacting medications are used; metabolic and liver labs at 12 weeks; then every 6–12 months while use continues